Evidence map›Paper›PMID 24825236›Full record

ArticleAmerican journal of public health2014

Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.

Jemima A Frimpong, Thomas D'Aunno, Lan Jiang

Open access · greenAbstract read
In one paragraph

Article in American journal of public health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2020
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Opioid epidemic and liver disease.JHEP reports : innovation in hepatology · 2019
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jemima A FrimpongJemima A. Frimpong and Thomas D'Aunno are with the Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, NY. Lan Jiang is with the Providence Veterans Affairs Medical Center, Providence, RI.
Thomas D'Aunno
Lan Jiang
Providence VA Medical Center · US

Funding

CTSA: K12 COMPONENTKL2RR024157 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$8.9M
Clinical and Translational Science AwardKL2TR000081 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$3.3M
Testing a Comprehensive Model of the Diffusion of Evidence-Based PracticesR01DA030459 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI D'AUNNO, THOMAS · 2011 to 2012
$926k
NCATS NIH HHS KL2 TR000081NCRR NIH HHS KL2 RR024157NIDA NIH HHS R01 DA030459
6 · The paper itself

Abstract

objectivesWe examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs.

methodsWe used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability.

resultsBetween 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios.

conclusionsThe increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability of HCV testing in opioid treatment programs.

Indexed as

Financing, GovernmentHealth Care SurveysHealth Services AccessibilityHepatitis CHumansOpiate Substitution TreatmentOpioid-Related DisordersSubstance Abuse Treatment CentersUnited States

Identifiers

PMID24825236
PMCPMC4062014
OpenAlexW2114683923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.